Recent studies showed that compounds with dual glutaminase inhibition and Nrf2 activation activities effectively prevent diseases such as chemotherapy-induced peripheral neuropathy (Foster et al., 2025). The gene discussed is GLS; the disease is peripheral neuropathy.